Seqirus Inc.
Global influenza vaccine manufacturer focused on seasonal and pandemic preparedness. Operates multiple manufacturing sites using cell-culture and egg-based production, develops adjuvanted and next-generation vaccine formulations, supports clinical development and regulatory processes, and conducts real-world evidence and surveillance-focused analyses.
Industries
N/A
Nr. of Employees
medium (51-250)
Patents
Products
Adjuvanted trivalent influenza vaccine (indicated for older adults)
Inactivated, adjuvanted trivalent influenza vaccine indicated for active immunization against specified influenza strains in older adults.
Cell-culture-derived quadrivalent influenza vaccine
Inactivated cell-based quadrivalent influenza vaccine indicated for active immunization against specified influenza A and B strains for pediatric and adult populations.
FLUAD
Adjuvanted influenza vaccine offered by CSL Seqirus.
FLUAD TRIVALENT
FLUAD TRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine, approved for use in persons 65 years of age and older.
FLUCELVAX TRIVALENT
FLUCELVAX TRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine, approved for use in persons 6 months of age and older.
Adjuvanted trivalent influenza vaccine (indicated for older adults)
Inactivated, adjuvanted trivalent influenza vaccine indicated for active immunization against specified influenza strains in older adults.
Cell-culture-derived quadrivalent influenza vaccine
Inactivated cell-based quadrivalent influenza vaccine indicated for active immunization against specified influenza A and B strains for pediatric and adult populations.
FLUAD
Adjuvanted influenza vaccine offered by CSL Seqirus.
FLUAD TRIVALENT
FLUAD TRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine, approved for use in persons 65 years of age and older.
FLUCELVAX TRIVALENT
FLUCELVAX TRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine, approved for use in persons 6 months of age and older.
Services
Collaborative agreements, licensing, joint ventures and strategic investments to advance vaccine technologies and commercialization.
Provision of pre-pandemic and pandemic vaccine doses, reserved manufacturing capacity, and coordination with governments for emergency response.
Support for externally initiated research studies through medical affairs collaboration.
Medical information services for healthcare providers and dedicated channels for adverse event reporting.
Collaborative agreements, licensing, joint ventures and strategic investments to advance vaccine technologies and commercialization.
Provision of pre-pandemic and pandemic vaccine doses, reserved manufacturing capacity, and coordination with governments for emergency response.
Support for externally initiated research studies through medical affairs collaboration.
Medical information services for healthcare providers and dedicated channels for adverse event reporting.
Expertise Areas
- Vaccine manufacturing (cell-culture and egg-based)
- Fill-and-finish operations and scale-up
- Pandemic preparedness and surge production
- Adjuvanted vaccine formulation
Key Technologies
- Cell-culture vaccine production
- Egg-based vaccine production
- Oil-in-water emulsion adjuvants (antigen-sparing)
- mRNA and next-generation vaccine platforms
News & Updates
Announcement of expanded U.S. vaccine availability after completion of a manufacturing campaign.
RWE estimating ~19.8% relative vaccine effectiveness of cell-based quadrivalent vaccines versus standard egg-based vaccines for the 2023/24 U.S. season.
Multiple BARDA awards to support fill-and-finish and expansion of adjuvant reserves for national pre-pandemic stockpiles.
Announcement of expanded U.S. vaccine availability after completion of a manufacturing campaign.
RWE estimating ~19.8% relative vaccine effectiveness of cell-based quadrivalent vaccines versus standard egg-based vaccines for the 2023/24 U.S. season.
Multiple BARDA awards to support fill-and-finish and expansion of adjuvant reserves for national pre-pandemic stockpiles.